Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: A comparison of assay results from three Italian centres

Francesca Bellomi, Placido Bramanti, Maria Trojano, Carolina Scagnolari, Antonella Muto, Edoardo Sessa, Vito La Volpe, Pierluigi Russo, Guido Antonelli

Research output: Contribution to journalArticle

Abstract

Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84% agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.

Original languageEnglish
Pages (from-to)40-50
Number of pages11
JournalJournal of Immunoassay and Immunochemistry
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2009

Keywords

  • Antibodies to interferon
  • Interferon beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Biochemistry
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: A comparison of assay results from three Italian centres'. Together they form a unique fingerprint.

  • Cite this